78 results on '"Bardazzi, F."'
Number of results to display per page
Search Results
2. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
- Author
-
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, and Aloisi E
- Subjects
psoriasis ,secukinumab ,real-world evidence ,drug survival ,supreme ,Dermatology ,RL1-803 - Abstract
Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,† Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Section of Dermatology, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genova, Italy; 14Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 15Section of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 16Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 17Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 18Section of Dermatology, Department of Medical and Surgical Specialties, University of Catania, Catania, Italy; 19Dermatology Clinic of Terni, University of Perugia, Perugia, Italy; 20Section of Dermatology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 21Department of Health Sciences, Magna Graecia University, Catanzaro, Italy; 22Department of Medicine and Surgery, University of Parma, Parma, Italy; 23Section of Dermatology, Department of Biotechnological and Applied Clinical Science, University of L’Aquila, L’Aquila, Italy; 24Department of Dermatology, Istituto Dermopatico dell’Immacolata - IRCCS, Roma, Italy; 25Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Dermatology Unit, “Daniele Innocenzi”, Asl Latina, Italy; 26Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 27Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; 28Dermatology Unit, Lucca Azienda USL Toscana Nord Ovest, Pisa, Italy; 29Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; 30Department of Dermatology, University of Trieste, Trieste, Italy; 31Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 32Department of Dermatology, University of Bari, Bari, Italy; 33Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; 34Dermatology Unit, Vito Fazzi Hospital, Lecce, Italy; 35Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy; 36Dermatology Unit, IRCCS IO Galeazzi, Milan, Italy; 37Dermatological Clinic, Polytechnic University of the Marche Region, Ancona, Italy; 38Department of Dermatology, Istituto Dermatologico San Gallicano - IRCCS, Roma, Italy; 39Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 40Novartis Farma SpA, Origgio, Italy; 41National Centre for Healthcare Research and Pharmacoepidemiology, Milan, Italy; 42Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy†Gabriella Fabbrocini passed away on 3 March 2023Correspondence: Filomena Russo, Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy, Email file.russo@libero.itPurpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings.Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.Keywords: psoriasis, secukinumab, real-world evidence, drug survival, SUPREME
- Published
- 2023
3. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
- Author
-
Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fargnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, and Costanzo A
- Subjects
psoriasis ,biologics ,interleukin-17a ,secukinumab ,elderly ,Dermatology ,RL1-803 - Abstract
Marina Talamonti,1 Filomena Russo,2 Giovanna Malara,3,4 Katharina Hansel,5 Manuela Papini,6 Angelo Cattaneo,7 Aurora Parodi,8 Andrea Chiricozzi,9,10 Piergiorgio Malagoli,11 Federico Bardazzi,12 Valeria Brazzelli,13 Paolo Dapavo,14 Paolo Gisondi,15 Cristina Zane,16 Concetta Potenza,17 Franca Cantoresi,18 Maria Concetta Fargnoli,19 Sara Trevisini,20 Pina Brianti,21 Leonardo Pescitelli,22 Giovanni Gigante,23 Marta Bartezaghi,23 Luisa Caputo,23 Elisabetta Aloisi,23 Antonio Costanzo24,25 On behalf of the SUPREME Study Group1Dermatology, University of Rome Tor Vergata, Rome, Italy; 2Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy; 3Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio, Calabria, Italy; 4Department of Dermatology, Papardo Hospital, Messina, Italy; 5Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 6Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 7U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 8Di.S.Sal. Section of Dermatology, Ospedale Policlinico San Martino, University of Genova, Genova GE, 16132, Italy; 9UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; 10Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; 11Psocare Unit, I.R.C.C.S Policlinico San Donato, Milano, Italy; 12Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 13Dermatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 14Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Torino, Torino, Italy; 15Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy; 16Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; 17Dermatology Unit “Daniele Innocenzi”, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome – Polo Pontino, Latina, Italy; 18Dermatology Unit, Department of Medicine, University of Roma, Roma, Italy; 19Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 20Department of Dermatology, University of Trieste, Trieste, Italy; 21Dermatology and Cosmetology Unit - San Raffaele Hospital, Milan, Italy; 22Department of Health Sciences, Dermatology Clinic, University of Firenze, Firenze, Italy; 23Novartis Farma SpA, Origgio, Italy; 24Unit of Dermatology, IRCCS Humanitas Research Hospital, Milano, Italy; 25Department of Biomedical Sciences, Humanitas University, Milano, ItalyCorrespondence: Marina Talamonti, Dermatology-Department of Systems Medicine, University of Rome Tor Vergata, PTV – Policlinico Tor Vergata, V.le Oxford 81, Rome, 00133, Italy, Tel +39 0620902743, Fax +39 0620902742, Email talamonti.marina@gmail.comPurpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study.Patients and Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month. We compared the following outcomes in patients aged ≥ 65 years vs < 65 years: baseline characteristics; PASI50/75/90/100 response rates (improvements ≥ 50%/75%/90%/100% in Psoriasis Area and Severity Index (PASI) from baseline); changes in Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Scale (HAD-A, HAD-D) score changes; treatment-emergent adverse events (TEAEs).Results: Secukinumab was slightly less effective in elderly patients than in adult patients (response rates at week 16: PASI90, 69.4% vs 80.9%, p = 0.4528; PASI100, 44.4% vs 56.7%, p = 0.8973). Elderly and adult patients showed a similar time course of changes in absolute PASI scores. Patients aged ≥ 65 years had a statistically significantly lower improvement in quality of life (mean DLQI reduction) than patients aged < 65 years at week 16 [− 5.4 (± 4.3) vs − 8.8 (± 6.9), p = 0.0065] and at week 24 [− 5.3 (± 4.4) vs − 9.2 (± 7.1), p = 0.0038]. Secukinumab treatment resulted in comparable mean reductions in anxiety and depression scores in both cohorts at 24 weeks [HAD-A, − 1.3 (± 3.3) vs − 2.1 (± 3.8), p = 0.9004; HAD-D, − 1.0 (± 3.3) vs − 1.5 (± 3.1), p = 0.4598]. The frequency of TEAEs in the two cohorts was similar (16.7% vs 14.6%, p = 0.7391).Conclusion: Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.Keywords: psoriasis, biologics, interleukin-17A, secukinumab, elderly
- Published
- 2023
4. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
- Author
-
Stingeni L, Malara G, Conti A, Di Costanzo L, Carrera CG, Burlando M, Malagoli P, Musumeci ML, Bardazzi F, Brazzelli V, Amerio P, De Simone C, Trevisini S, Balato A, Megna M, Loconsole F, De Felice C, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, and Costanzo A
- Subjects
plaque psoriasis ,pasi ,patient-reported outcomes ,dermatology quality of life index ,hospital anxiety and depression scale ,Dermatology ,RL1-803 - Abstract
Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Trevisini,15 Anna Balato,16 Matteo Megna,17 Francesco Loconsole,18 Catia De Felice,19 Marta Bartezaghi,20 Alice Rausa,20 Elisabetta Aloisi,20 Roberto Orsenigo,20 Antonio Costanzo21,22 On behalf of the SUPREME Study Group1Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy; 2Dermatology Unit, Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy; 3Department of Dermatology, Papardo Hospital, Messina, Italy; 4Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 5Department of Dermatology, “Gaetano Rummo” Hospital, Benevento UOC Dermatologia, AO G. Rummo, Benevento, Italy; 6U.O. Dermatologia, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 7IRCCS San Martino Polyclinic Hospital, Di.S.Sal. Section of Dermatology, Genoa, Italy; 8Dermatology Unit IRCCS Policlinico San Donato, Milan, Italy; 9Dermatology Clinic, University of Catania, Catania, Italy; 10Division of Dermatology, University Hospital Policlinico “S. Orsola-Malpighi”, Bologna, Italy; 11Institute of Dermatology, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 12Dermatologic Clinic, G. D’Annunzio University, Chieti, Italy; 13Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 14Fondazione Policlinico Universitario A. Gemelli – IRCCS, Rome, Italy; 15Dermatology Department, University of Trieste, Trieste, Italy; 16Dermatology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy; 17Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 18Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 19Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy; 20Novartis Farma SpA, Origgio, Italy; 21Unit of Dermatology, IRCCS Humanitas Research Hospital, Milan, Italy; 22Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence: Luca Stingeni, Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy, Tel +39075-5783881, Email luca.stingeni@unipg.itPurpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.Patients and Methods: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.Results: Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P< 0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (− 10.9 vs − 8.1, respectively, in females vs males; P=0.0004).Conclusion: In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.Keywords: plaque psoriasis, PASI, patient-reported outcomes, Dermatology Quality of Life Index, Hospital Anxiety and Depression Scale
- Published
- 2023
5. Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis
- Author
-
Colombo D, Chimenti S, Grossi PA, Marchesoni A, Bardazzi F, Ayala F, Simoni L, Vassellatti D, and Bellia G
- Subjects
Gender medicine ,psoriatic arthritis ,cyclosporine ,viral infections ,Dermatology ,RL1-803 - Abstract
Delia Colombo,1 Sergio Chimenti,2 Paolo Antonio Grossi,3 Antonio Marchesoni,4 Federico Bardazzi,5 Fabio Ayala,6 Lucia Simoni,7 Donatella Vassellatti,1 Gilberto Bellia1 On behalf of SYNERGY Study Group 1Novartis Farma Italia, Origgio (VA), 2Tor Vergata Polyclinic Rome, 3Macchi Hospital and Foundation, Varese, 4Orthopaedic Institute Pini, Milan, 5S Orsola-Malpighi Polyclinic, Bologna, 6University Federico II Naples, 7MediData srl, Modena, Italy Background: Sex medicine studies have shown that there are sex differences with regard to disease characteristics in immune-mediated inflammatory diseases, including psoriasis, in immune response and susceptibility to viral infections. We performed a post hoc analysis of the Observational Study of infectious events in psoriasis complicated by active psoriatic arthritis (SYNERGY) study in patients with psoriatic arthritis (PsA) treated with immunosuppressive regimens including cyclosporine, in order to evaluate potential between-sex differences in severity of disease and prevalence of viral infections.Methods: SYNERGY was an observational study conducted in 24 Italian dermatology clinics, which included 238 consecutively enrolled patients with PsA, under treatment with immunosuppressant regimens including cyclosporin A. In this post hoc analysis, patients' demographical data and clinical characteristics of psoriasis, severity and activity of PsA, prevalence of seropositivity for at least one viral infection, and treatments administered for PsA and infections were compared between sexes.Results: A total of 225 patients were evaluated in this post hoc analysis, and 121 (54%) were males. Demographic characteristics and concomitant diseases were comparable between sexes. Statistically significant sex differences were observed at baseline in Psoriasis Area and Severity Index score (higher in males), mean number of painful joints, Bath Ankylosing Spondylitis Disease Activity Index, and the global activity of disease assessed by patients (all higher in females). The percentage of patients with at least one seropositivity detected at baseline, indicative of concomitant or former viral infection, was significantly higher among women than among men. No between-sex differences were detected in other measures, at other time points, and in treatments. Patients developed no hepatitis B virus or hepatitis C virus reactivation during cyclosporine treatment.Conclusion: Our post hoc sex analysis suggests that women with PsA have a greater articular involvement and a higher activity of disease compared to males. Immunosuppressive treatment with cyclosporine seems not to increase susceptibility to new infections or infectious reactivations, with no sex differences. Keywords: psoriatic arthritis, sex, viral infections, SYNERGY, cyclosporine
- Published
- 2015
6. Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt)
- Author
-
Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Cac-Cavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M., Russo, A., Simonetti, O., Borghi, A., Corazza, M., Piaserico, S., Feliciani, C., Calzavara-Pinton, P., Amendolagine, G., Arisi, M., Babino, G., Bardazzi, F., Belloni Fortina, A., Caccavale, S., Campanati, A., Campione, E., Caposiena, C. D., Carugno, A., Coati, I., Cinotti, E., D'Antuono, A., Dattola, A., Dika, E., Fai, D., Fusano, M., Galluzzo, M., Ganzetti, G., Gisondi, P., Hansel, K., Lora, V., Maione, V., Mandel, V. D., Menni, S., Negosanti, M., Neri, I., Offidani, A., Parodi, A., Patrizi, A., Peserico, A., Rossi, M., Rivetti, N., Saccani, E., Stan, T. R., Stingeni, L., Talamonti, M., Vascellaro, A., Vezzoli, P., Virgili, A., Zanca, A., Papini, M, Russo, A, Simonetti, O, Borghi, A, Corazza, M, Piaserico, S, Feliciani, C, Calzavara-Pinton, P, Amendolagine, G, Arisi, M, Babino, G, Bardazzi, F, Belloni Fortina, A, Cac-Cavale, S, Campanati, A, Campione, E, Caposiena, C, Carugno, A, Coati, I, Cinotti, E, D'Antuono, A, Dattola, A, Dika, E, Fai, D, Fusano, M, Galluzzo, M, Ganzetti, G, Gisondi, P, Hansel, K, Lora, V, Maione, V, Mandel, V, Menni, S, Negosanti, M, Neri, I, Offidani, A, Parodi, A, Patrizi, A, Peserico, A, Rossi, M, Rivetti, N, Saccani, E, Stan, T, Stingeni, L, Talamonti, M, Vascellaro, A, Vezzoli, P, Virgili, A, Zanca, A, Papini M., Russo A., Simonetti O., Borghi A., Corazza M., Piaserico S., Feliciani C., Calzavara-Pinton P., Amendolagine G., Arisi M., Babino G., Bardazzi F., Belloni Fortina A., Cac-Cavale S., Campanati A., Campione E., Caposiena C.D., Carugno A., Coati I., Cinotti E., D'Antuono A., Dattola A., Dika E., Fai D., Fusano M., Galluzzo M., Ganzetti G., Gisondi P., Hansel K., Lora V., Maione V., Mandel V.D., Menni S., Negosanti M., Neri I., Offidani A., Parodi A., Patrizi A., Peserico A., Rossi M., Rivetti N., Saccani E., Stan T.R., Stingeni L., Talamonti M., Vascellaro A., Vezzoli P., Virgili A., and Zanca A.
- Subjects
Male ,medicine.medical_specialty ,Calcineurin Inhibitors ,Socio-culturale ,Disease ,Dermatology ,Lichen sclerosus ,Guideline ,Settore MED/35 ,Lichen sclerosus et atrophicu ,medicine ,Dysuria ,Humans ,Sex organ ,Drug therapy ,Lichen sclerosus et atrophicus ,Operative surgical procedures ,Rare diseases ,Vulvar lichen sclerosus ,Female ,Italy ,Mometasone Furoate ,Lichen Sclerosus et Atrophicus ,Calcineurin Inhibitor ,business.industry ,Mucous membrane ,Evidence-based medicine ,medicine.disease ,Infectious Diseases ,medicine.anatomical_structure ,Sexual dysfunction ,Operative surgical procedure ,Vulvar lichen sclerosu ,medicine.symptom ,business ,Rare disease ,Human - Abstract
Lichen sclerosus (LS) is a disabling chronic inflammatory disease of skin and genital mucous membrane causing itch, pain, dysuria and restriction of micturition, and significant sexual dysfunction and dyspareunia both in women and men. If left untreated, LS is associated with a high degree of sclerosis and scarring, as well as with an elevated risk of cancer in the genital area. Although a central role of autoimmunity is suggested, the pathogenesis of LS is still not clearly understood and the disease remains difficult to treat. The goals of treatment of LS are to alleviate symptoms and discomfort, prevent anatomical changes and prevent malignant transformation. This guideline has been developed by an Italian group of experts. It summarizes evidence-based and expert- based recommendations. The highest level of evidence favors the use of topical high potency corticosteroids; second- and third-line treatments include topical calcineurin inhibitors and topical retinoids, respectively. Surgical treatment has become the treatment of choice in male genital LS with persistent phimosis not responsive to medical treatment. The aim of this paper is to offer evidence-based and easily applicable recommendations for the management of LS.
- Published
- 2021
7. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience
- Author
-
Fargnoli M. C., Esposito M., Dapavo P., Parodi A., Rossi M., Tiberio R., Dastoli S., Offidani A. M., Argenziano G., Gisondi P., Lo Schiavo A., Loconsole F., Pella P., Bardazzi F., Cusano F., Gattoni M., Nacca M., Cannavo S. P., Pellegrini C., Costanzo A., Pertusi G., Stroppiana E., Gambardella A., Romano F., Sassetti C., Carpentieri A., Bellinato F., Burlando M., Graziola F., Sacchelli L., Campanati A., Ronza G., Fargnoli, M. C., Esposito, M., Dapavo, P., Parodi, A., Rossi, M., Tiberio, R., Dastoli, S., Offidani, A. M., Argenziano, G., Gisondi, P., Lo Schiavo, A., Loconsole, F., Pella, P., Bardazzi, F., Cusano, F., Gattoni, M., Nacca, M., Cannavo, S. P., Pellegrini, C., Costanzo, A., Pertusi, G., Stroppiana, E., Gambardella, A., Romano, F., Sassetti, C., Carpentieri, A., Bellinato, F., Burlando, M., Graziola, F., Sacchelli, L., Campanati, A., and Ronza, G.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Brodalumab ,Dermatology ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Quality of life ,Psoriasis Area and Severity Index ,Psoriasis ,Internal medicine ,medicine ,Humans ,Adverse effect ,Retrospective Studies ,business.industry ,Antibodies, Monoclonal ,Retrospective cohort study ,Dermatology Life Quality Index ,Middle Aged ,medicine.disease ,Treatment Outcome ,Infectious Diseases ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,business - Abstract
Background: Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. Objectives: To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. Methods: This observational, retrospective study enrolled adult patients (≥18years) with moderate-to-severe plaque-type psoriasis who underwent 24weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. Results: Seventy-eight patients (mean age 47.9years, 71.8% male, average disease duration 16.8years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4weeks of treatment, decreasing further at weeks 12 and 24 (all P 
- Published
- 2021
8. Pruritus characteristics in a large Italian cohort of psoriatic patients
- Author
-
Damiani, G., Cazzaniga, S., Conic, R. R. Z., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnu, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., Amico, Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., Gonzalez Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo, S., Manfre, C., Borgia, F., Puglisi Guerra, A., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Arico, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvara, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigo, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappala, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Damiani G., Cazzaniga S., Conic R.R.Z., Naldi L., Griseta V., Miracapillo A., Azzini M., Mocci L., Michelini M., Offidani A., Bernardini L., Campanati A., Ricotti G., Giacchetti A., Norat M., Gualco F., Castelli A., Cuccia A., Diana A., Roncarolo G., Belli M.A., Baldassarre M.A., Santoro G., Vena G.A., Lo Console F., Filotico R., Mastrandrea V., Brunetti B., Musumeci F., Carrabba E., Dal Mas P., Annicchiarico F., Benvegnu B., Spaziani G., Cusano F., Saletta Iannazzone S., Galluccio A., Pezza M., Marchesi L., Imberti G., Reseghetti A., Barbera C., Reggiani M., Lanzoni A., Patrizi A., Bardazzi F., Antonucci A., De Tommaso S., Wallnofer W., Ingannamorte F., Calzavara-Pinton P., Iannazzi S., Zane C., Capezzera R., Bassisi S., Rossi M.T., Altamura V., Vigl W., Nobile C., Aste N., Murgia S., Mugheddu C., Scuderi G., Baglieri F., Di Dio C., Cilioni Grilli E., Mastronardi C., Agnusdei C.P., Antrilli A., Aulisa L., Raimondo U., Scotto di Luzio G., Battarra V.C., Farro P., Plaitano R., Micali G., Musumeci M.L., Massimino D., Li Calzi M., La Greca S., Pettinato M., Sapienza G., Valenti G., De Giacomo P.F., Amico, Arcangeli F., Brunelli D., Ghetti E., Tulli A., Assi G., Amerio P., Laria G., Prestinari F., Spadafora S., Coppola M., Caresana G., Pezzarossa E., Felisi C., Donato L., Bertero M., Musso L., Pa lazzini S., Bruscino P., Agozzino U.C., Ottaviani M., Simoncini C., Virgili A., Osti F., Fabbri P., Volpi W., Caproni M., Lotti T., Prignano F., Buggiani G., Troiano M., Fenizi G., Altobella A., Amoruso A., Condello M., Goffredo A., Righini M.G., Alessandrini F., Satolli F., Zampetti M., Bertani E., Fossati S., Parodi A., Burlando M., Fiorucci C., Nigro A., Ghigliotti G., Massone L., Moise G.M., Serrai M., Cannata G., Campagnoli A.M., Daly M., Leporati C., Peila R., Filosa G., Bugatti L., Nicolini M., Nazzari G., Cestari R., Anastasio F., Larussa F.M., Pollice N., De Francesco F., Mazzocchetti G., Peris K., Fargnoli M.C., Di Cesare A., De Angelis L., Flati G., Biamonte A.S., Quarta G., Congedo M., Carcaterra A., Strippoli D., Fideli D., Marsili F., Celli M., Ceccarini M., Bachini L., D'Oria M., Schirripa V., De Filippi C., Martini P., Lapucci E., Mazzatenta C., Ghilardi A., Simonacci M., Bettacchi A., Gasco R., Zanca A., Battistini S., Dattola S., Vernaci R., Postorino F., Zampieri P.F., Padovan C., Gonzalez Intchaurraga M.A., Ladurner J., Guarneri B., Cannavo S., Manfre C., Borgia F., Puglisi Guerra A., Cattaneo A., Carrera C., Fracchiolla C., Mozzanica N., Prezzemolo L., Menni S., Lodi A., Martino P., Monti M., Mancini L., Sacrini F., Altomare G.F., Taglioni M., Lovati C., Mercuri S.R., Schiesari G., Giannetti A., Conti A., Lasagni C., Greco M., Ronsini G., Schianchi S., Fiorentini C., Niglietta S., Maglietta R., Padalino C., Crippa D., Pini M., Rossi E., Tosi D., Armas M., Ruocco V., Ayala F., Balato N., Gaudiello F., Cimmino G.F., Monfrecola G., Gallo L., Argenziano G., Fulgione E., Berruti G., Ceparano S., De Michele I., Giorgiano D., Leigheb G., Deledda S., Peserico A., Alaibac M., Piaserico S., Schiesari L., Dan G., Mattei I., Oro E., Arico M., Bongiorno M.R., Angileri R., Amato S., Todaro F., Milioto M., Bellastro R., Di Nuzzo S., De Panfilis G., Zanni M., Borroni G., Cananzi R., Brazzelli V., Lisi P., Stingeni L., Hansel K., Pierfelice V., Donelli S., Rastelli D., Gasperini M., Barachini P., Cecchi R., Bartoli L., Pavesi M., De Paola S., Corradin M.T., Ricciuti F., Piccirillo A., Viola L., Tataranni M., Mautone M.G., Lo Scocco G., Niccoli M.C., Brunasso Vernetti A.M.G., Gaddoni G., Resta F., Casadio M.C., Arcidiaco M.C., Luvara M.C., Albertini G., Di Lernia V., Guareschi E., Catrani S., Morri M., De Simone C., D'Agostino M., Agostino I., Calvieri S., Cantoresi F., Richetta A., Sorgi P., Carnevale C., Nicolucci F., Berardesca E., Ardigo M., De Felice C., Gubinelli E., Talamonti M., Camplone G., Cruciani G., Riccardi F., Barbati R., Zumiani G., Pagani W., Malagoli P.G., Pellicano R., Donadio D., Di Vito C., Cottoni F., Montesu M.A., Pirodda C., Addis G., Marongiu P., Farris A., Cacciapuoti M., Verrini A., Desirello G., Gnone M., Fimiani M., Pellegrino M., Castelli G., Zappala L., Sesana G., Ingordo V., Vozza E., Di Giuseppe D., Fasciocco D., Nespoli P., Papini M., Cicoletti M., Bernengo M.G., Ortoncelli M., Bonvicino A., Capella G., Doveil G.C., Forte M., Peroni A., Salomone B., Savoia P., Pippione M., Zichichi L., Frazzitta M., De Luca G., Tasin L., Simonetto D., Ros S., Trevisan G., Patamia M., Miertusova S., Patrone P., Frattasio A., Piccirillo F., La Spina S., Di Gaetano L., Marzocchi V., Motolese A., Venturi C., Gai F., Pasquinucci S., Bellazzi R.M., Silvestri T., Girolomoni G., Gisondi P., Veller Fornasa C., and Trevisan G.P.
- Subjects
Male ,Cross-sectional study ,Severity of Illness Index ,Cohort Studies ,030207 dermatology & venereal diseases ,0302 clinical medicine ,Risk Factors ,education ,itch ,pruritus ,psoriasis ,pustular psoriasis ,treatment ,Adolescent ,Adult ,Cross-Sectional Studies ,Educational Status ,Facial Dermatoses ,Female ,Foot Dermatoses ,Genitalia ,Hand Dermatoses ,Humans ,Italy ,Middle Aged ,Pruritus ,Psoriasis ,Registries ,Sex Factors ,Young Adult ,Epidemiology ,Young adult ,skin and connective tissue diseases ,Settore MED/33 - MALATTIE APPARATO LOCOMOTORE ,Infectious Diseases ,030220 oncology & carcinogenesis ,Cohort ,PRURITIS EPIDEMIOLOGY ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Cohort study ,medicine.medical_specialty ,PSORIAS ,Dermatology ,Article ,03 medical and health sciences ,Pharmacotherapy ,Settore MED/35 ,Severity of illness ,medicine ,business.industry ,medicine.disease ,Pruritus,Itch sensation ,business - Abstract
Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10802 patients, with a mean age 48.8±14.3years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and very severe in 13.7%. Higher itch intensity was associated with female gender, lower educational attainment compared to university degree, pustular psoriasis, psoriasis on the head, face, palmoplantar areas, folds and genitalia, more severe disease, disease duration
- Published
- 2019
9. Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry
- Author
-
Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, Griseta V, Psocare Study Group., Miracapillo, A, Azzini, M, Mocci, L, Michelini, M, Offidani, A, Bernardini, L, Campanati, A, Ricotti, G, Giacchetti, Alessandro, Norat, M, Gualco, F, Castelli, A, Cuccia, A, Diana, A, Roncarolo, G, Belli, Ma, Baldassarre, Ma, Santoro, G, Vena, Ga, Lo Console, F, Filotico, R, Mastrandrea, V, Brunetti, B, Musumeci, F, Carrabba, E, Dal Mas, P, Annicchiarico, F, Benvegnù, B, Spaziani, G, Cusano, F, Saletta Iannazzone, S, Galluccio, A, Pezza, M, Marchesi, L, Imberti, G, Reseghetti, A, Barbera, Claudia, Reggiani, Matteo, Lanzoni, A, Patrizi, A, Bardazzi, F, Antonucci, A, De Tommaso, S, Balestri, R, Wallnofer, W, Ingannamorte, F, Calzavara-Pinton, P, Iannazzi, S, Zane, C, Capezzera, R, Bassisi, S, Rossi, Mt, Altamura, V, Vigl, W, SCHETTINO NOBILE, Carla, Aste, N, Murgia, S, Mugheddu, C, Scuderi, G, Baglieri, F, Di Dio, C, Cilioni Grilli, E, Mastronardi, C, Agnusdei, Cp, Antrilli, A, Aulisa, L, Raimondo, U, Scotto di Luzio, G, Battarra, Vc, Farro, P, Plaitano, R, Micali, G, Musumeci, Ml, D'Armiento, Massimino, Li Calzi, M, LA GRECA, SEBASTIANO VITTORIO, Pettinato, Cristiana Maria, Sapienza, G, Valenti, G, De Giacomo PF, D'Amico, D, Arcangeli, Federica, Brunelli, D, Ghetti, E, Tulli, Augusta, Assi, G, Amerio, P, Laria, G, Prestinari, F, Spadafora, S, Coppola, M, Caresana, G, Pezzarossa, E, Domaneschi, E, Felisi, C, Donato, L, Bertero, M, Musso, L, Pa Lazzini, S, Bruscino, P, Agozzino, Uc, Ottaviani, M, Simoncini, Cristiana, Virgili, A, Osti, F, Fabbri, P, Volpi, Walter, Caproni, M, Lotti, T, Prignano, F, Buggiani, G, Troiano, M, Fenizi, G, Altobella, A, Amoruso, A, Condello, M, Goffredo, A, Righini, Mg, Alessandrini, F, Satolli, F, Zampetti, M, Bertani, E, Fossati, S, Parodi, A, Burlando, M, Fiorucci, C, Nigro, A, Ghigliotti, G, Massone, L, Moise, Gm, Serrai, M, Cannata, G, Campagnoli, Am, Daly, M, Leporati, C, Peila, R, Filosa, Giovanna, Bugatti, L, Nicolini, M, Nazzari, G, Cestari, R, Anastasio, Fabio, Larussa, Fm, Pollice, N, De Francesco, F, Mazzocchetti, G, Peris, K, Fargnoli, Mc, Di Cesare, A, De Angelis, L, Flati, G, Biamonte, As, Quarta, Giovanni, Congedo, M, Carcaterra, A, Strippoli, D, Fideli, D, Marsili, Filippo, Celli, M, Ceccarini, M, Bachini, L, D ORIA, MARIA FEDERICA, Schirripa, V, De Filippi, C, Martini, P, Lapucci, E, Mazzatenta, C, Ghilardi, A, Simonacci, M, Bettacchi, A, Gasco, R, Zanca, A, Battistini, Simone, Dattola, S, Vernaci, R, Postorino, F, Zampieri, Pf, Padovan, MARIA CRISTINA, González Intchaurraga MA, Ladurner, J, Guarneri, B, Cannavo', Serena, Manfrè, C, Borgia, F, Puglisi Guerra, A, Sedona, P, Cattaneo, A, Carrera, C, Fracchiolla, C, Mozzanica, N, Prezzemolo, L, Menni, S, Lodi, A, Martino, P, Monti, M, Mancini, L, Sacrini, F, Altomare, Gf, Taglioni, M, Lovati, C, Mercuri, Sr, Schiesari, G, Giannetti, A, Conti, A, Lasagni, C, Greco, M, Ronsini, G, Schianchi, S, Fiorentini, C, Niglietta, S, Miglietta, R, Padalino, C, Crippa, D, Pini, M, Rossi, E, Tosi, D, Armas, M, Ruocco, V, Ayala, F, Balato, N, Gaudiello, F, Cimmino, Gf, Monfrecola, G, Gallo, L, Argenziano, G, Fulgione, E, Berruti, G, Mozzillo, R, Ceparano, S, De Michele, I, Giorgiano, D, Leigheb, G, Deledda, S, Peserico, A, Alaibac, M, Piaserico, S, Schiesari, L, Dan, G, Mattei, I, Oro, E, Aricò, M, Bongiorno, Mr, Angileri, Rosalia, Amato, S, Todaro, F, Milioto, M, Bellastro, R, Di Nuzzo, S, De Panfilis, G, Zanni, M, Borroni, G, Cananzi, R, Brazzelli, V, Lisi, P, Stingeni, L, Hansel, K, Pierfelice, V, Donelli, S, Rastelli, D, Gasperini, M, Barachini, P, Cecchi, R, Bartoli, L, Pavesi, Maria Gabriella, De Paola, S, Corradin, Mt, Ricciuti, F, Piccirillo, Alessandro, Viola, L, Tataranni, M, Mautone, Mg, Lo Scocco, G, Niccoli, Mc, Brunasso Vernetti AM, Gaddoni, G, DI RESTA, Fabio, Casadio, Mc, Arcidiaco, Mc, Luvarà, Mc, ALBERTINI PETRONI, Guglielmo, DI LERNIA, Valerio, Guareschi, E, Catrani, S, Morri, M, De Simone, C, D'Agostino, M, Agostino, I, Calvieri, S, Cantoresi, F, Richetta, A, Sorgi, Paola, Carnevale, C, Nicolucci, F, Berardesca, E, Ardigò, M, De Felice, C, Gubinelli, E, Talamonti, Marina, Camplone, G, Cruciani, Giulio, Riccardi, F, Barbati, R, Zumiani, G, Pagani, W, Malagoli, Pg, Pellicano, R, Donadio, Diego, Di Vito, C, Cottoni, F, Montesu, Ma, Pirodda, C, Addis, G, Marongiu, P, Farris, A, Cacciapuoti, Anna Maria, Verrini, A, Desirello, G, Gnone, M, Fimiani, M, Pellegrino, M, Castelli, G, Zappalà, L, Sesana, G, Ingordo, V, Vozza, E, Di Giuseppe, D, Fasciocco, D, Nespoli, P, Papini, M, Cicoletti, M, Bernengo, Mg, Ortoncelli, M, Bonvicino, A, Capella, G, Doveil, Gc, Forte, M, Peroni, A, Salomone, B, Savoia, P, Pippione, M, Zichichi, Ludovica, Frazzitta, M, De Luca, G, Tasin, L, Simonetto, D, Ros, S, Trevisan, G, Patamia, M, Miertusova, S, Patrone, Pietro, Frattasio, A, Piccirillo, Fabiola, La Spina, S, Di Gaetano, L, Marzocchi, V, Motolese, A, Venturi, Caterina, Gai, Francesco, Pasquinucci, S, Bellazzi, Rm, Silvestri, Tommaso, Veller Fornasa, C, Trevisan, Gp., Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, the Psocare Study Group [.., Annalisa Patrizi, ], Trevisan, Giusto, Girolomoni, G., Maccarone, Sergio, Naldi, L., Gisondi, P., Cazzaniga, S., Chimenti, S., Maccarone, M., Picardo, M., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M.A., Baldassarre, M.A., Santoro, G., Vena, G.A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnù, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M.T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C.P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto Di Luzio, G., Battarra, V.C., Farro, P., Plaitano, R., Micali, G., Musumeci, M.L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P.F., D'Amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa Lazzini, S., Bruscino, P., Agozzino, U.C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M.G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G.M., Serrai, M., Cannata, G., Campagnoli, A.M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F.M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M.C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A.S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P.F., Padovan, C., González Intchaurraga, M.A., Ladurner, J., Guarneri, B., Cannavò, S.P., Manfrè, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G.F., Taglioni, M., Lovati, C., Mercuri, S.R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G.F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Mozzillo, R., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricò, M., Bongiorno, M.R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M.T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M.G., Lo Scocco, G., Niccoli, M.C., Brunasso Vernetti, A.M.G., Gaddoni, G., Resta, F., Casadio, M.C., Arcidiaco, M.C., Luvarà, M.C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigò, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P.G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M.A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalà, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M.G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G.C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R.M., Silvestri, T., Veller Fornasa, C., and Trevisan, G.P.
- Subjects
Registrie ,Male ,taiwan ,Antitubercular Agents ,Biological Factor ,quantiferon-tb-gold ,Antitubercular Agent ,Biological Factors ,experience ,Residence Characteristics ,80 and over ,Prevalence ,Registries ,Young adult ,risk ,Aged, 80 and over ,Latent Tuberculosi ,Latent tuberculosis ,psoriasis ,Middle Aged ,Italy ,Female ,tubercolosis ,tubercolosi ,Adolescent ,Adult ,Age Distribution ,Aged ,Chronic Disease ,Humans ,Latent Tuberculosis ,PUVA Therapy ,Psoriasis ,Sex Distribution ,Tuberculin Test ,Young Adult ,2708 ,Human ,medicine.drug ,medicine.medical_specialty ,chronic plaque psoriasis ,Tuberculin ,consensus statement ,Dermatology ,tuberculosis infection ,Settore MED/35 ,Internal medicine ,medicine ,Adalimumab ,factor antagonists ,necrosis-factor blockers ,systemic treatment ,therapy ,assay ,Psoriasi ,History of tuberculosis ,tuberculosis infection, chronic plaque psoriasis,Italian Psocare Registry ,business.industry ,Odds ratio ,medicine.disease ,bacterial infections and mycoses ,Confidence interval ,Surgery ,Residence Characteristic ,Italian Psocare Registry ,business - Abstract
SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8·3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4·3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen–ultraviolet A (P
- Published
- 2015
10. Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors—first cohort from the EADV Task Force 'Dermatology for Cancer Patients'.
- Author
-
Ortiz-Brugués, A., Starace, M., Bardazzi, F., Koumaki, D., Apalla, Z., Iorizzo, M., Bost, C., Tournier, E., Milesi, S., Lacaze, J.L., Peris, K., Sollena, P., and Sibaud, V.
- Subjects
- *
TASK forces , *AUTOIMMUNE diseases , *CANCER patients , *DERMATOLOGY - Published
- 2024
- Full Text
- View/download PDF
11. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry
- Author
-
Piaserico, Stefano, Cazzaniga, Simone, Chimenti, Sergio, Giannetti, Alberto, Maccarone, Mara, Picardo, Mauro, Peserico, Andrea, Naldi, Luigi, Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnã¹, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., D’amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D’oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., González Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo', S., Manfrã, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricã², M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvarã , M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D’agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigã², M., De Felice, C., Gubinelli, E., Chimenti, S., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalã , L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L, Psocare Study Group [.., Patrizi A, ], Piaserico, S, Cazzaniga, S, Chimenti, S, Giannetti, A, Maccarone, M, Picardo, M, Peserico, A, Naldi, L, Bongiorno, MR, Psocare Study Group, Monfrecola, Giuseppe, and Trevisan, Giusto
- Subjects
Male ,primary inefficacy ,75% improvement in the Psoriasis Area Severity Index score ,PASI ,PASI 75 ,Psoriasis Area Severity Index ,TNF ,biologics ,efficacy ,psoriasis ,secondary loss of efficacy ,switching ,tumor necrosis factor ,tumor necrosis factor-alfa inhibitors ,Adult ,Analysis of Variance ,Antibodies, Monoclonal ,Antibodies, Monoclonal, Humanized ,Cohort Studies ,Confidence Intervals ,Dose-Response Relationship, Drug ,Drug Administration Schedule ,Female ,Follow-Up Studies ,Humans ,Immunoglobulin G ,Italy ,Middle Aged ,Multivariate Analysis ,Predictive Value of Tests ,Proportional Hazards Models ,Psoriasis ,Receptors, Tumor Necrosis Factor ,Registries ,Retrospective Studies ,Risk Assessment ,Severity of Illness Index ,Treatment Outcome ,Tumor Necrosis Factor-alpha ,Young Adult ,SWITHCES ,psoriasis arthritis ,pharmachological treatment ,Etanercept ,Monoclonal ,Receptors ,Settore MED/35 - Malattie Cutanee E Veneree ,Humanized ,Hazard ratio ,Predictive value of tests ,Drug ,biologic ,TNF-alpha ,medicine.medical_specialty ,Dermatology ,Antibodies ,Dose-Response Relationship ,Settore MED/35 ,Internal medicine ,Severity of illness ,medicine ,Adverse effect ,psoriasi ,Adalimumab ,Infliximab ,2708 ,Proportional hazards model ,business.industry ,tumor necrosis factor-alfa inhibitor ,Retrospective cohort study ,medicine.disease ,Confidence interval ,Surgery ,ANTI-TNFA ,business - Abstract
Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). Limitations: There was a small number of patients with complete follow-up data. Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa.
- Published
- 2014
12. Letter to the editor
- Author
-
Patrizi A, Bardazzi F, C Orlandi, and Vincenzi C
- Subjects
medicine.medical_specialty ,chemistry.chemical_compound ,Chemistry ,medicine ,Dermatology ,medicine.disease ,Sorbic acid ,Allergic contact dermatitis - Published
- 1999
13. Mercurochrome-induced allergic contact dermatitis.
- Author
-
Bardazzi, F., Vassilopoulou, A., Valenti, R., Paganini, P., and Morfiit, R.
- Subjects
- *
SKIN inflammation , *DENTAL amalgams , *SKIN diseases , *ALLERGIES , *ANTISEPTICS , *DERMATOLOGY - Abstract
This article presents a case study of a 9 year old child afflicted with redness, swelling and itching on finger of her right hand and on her right cheek patch testing was performed on the patient as part of the treatment. This study has led researchers to sum up that contact allergy to metallic mercury arise from topical medicaments, broken thermometer and dental amalgam. The case, however, illustrates mercurochrome cross-sensitization with organic compounds. Even though, this compound is widely used as a skin antiseptic, sensitization to mercurochrome has infrequently been reported.
- Published
- 1990
- Full Text
- View/download PDF
14. Contact dermatitis from rubidium iodide in eyedrops.
- Author
-
Camell, N., Bardazzi, F., Moretti, R., and Tosti, A.
- Subjects
- *
SKIN inflammation , *SYMPTOMS , *OPHTHALMIC drugs , *SKIN diseases , *DERMATOLOGY , *CASE studies - Abstract
This article presents a case study of 70 year old man presented with sever facial dermatitis. His symptoms had appeared five months after starting on an ophthalmic preparation for the treatment of cataracts. This study has led to sum up that contact allergy to ophthalmic preparations is a common problem, preservatives being the most frequent sensitizes. The above case study also illustrates the importance of patch testing with the individual constituents of ophthalmic preparations. Negative patch test reactions to eye-drops don't exclude the possibility of contact sensitization to one or more of the ingredients of those eye-drops.
- Published
- 1990
- Full Text
- View/download PDF
15. Systemic reactions due to thiomersal.
- Author
-
Tosti, A., Melino, M., and Bardazzi, F.
- Subjects
VACCINES ,PARENTERAL solutions ,URTICARIA ,DERMATOLOGY ,INJECTIONS - Abstract
This article reports on case studies of patients suffering from systematic reactions caused due to the preservative vaccine "thiomersal." The first case study reports on a 66 year-old woman who was admitted with acute urticaria 3 days after she had been vaccinated against influenza with a vaccine containing 0.01% thiomersal concentration. The rash disappeared within a few days without the treatment. The second case study presents information of a 31-year-old doctor, who developed acute urticaria one day after vaccination against hepatitits B with a vaccine containing 0.05% of thiomersal. Both patients presented a sytematic cutaneous reaction after injection of parenteral solutions containing thiomersal as preservative. Since the patch tests revealed sensitization it was believed that systematic reactions was caused due to the presence of Thiomersal.
- Published
- 1986
- Full Text
- View/download PDF
16. Contact dermatitis due to chlorpheniramine maleate in eyedrops.
- Author
-
Tosti, A., Bardazzi, F., and Piancastelli, E.
- Subjects
- *
CONTACT dermatitis , *CROMOLYN sodium , *ALLERGIES , *DELAYED hypersensitivity , *DERMATOLOGY , *ANTIHISTAMINES - Abstract
Although topical antihistamines are a frequent cause of contact dermatitis, contact sensitization to chlorpheniramine maleate, an antihistamine group, is reported to be rare. A 45-year old housewife had a chronic eczema of the face for 4 years. She had not been using topical medicaments or cosmetics there, with the exception of eyedrops used in the treatment of chronic conjunctivitis. Patch tests with the GIRDCA standard series and photopatch tests were negative. The patient had sporadically used an antihistamine cream containing chlorpheniramine maleate for the treatment of insect bites.
- Published
- 1990
- Full Text
- View/download PDF
17. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study
- Author
-
Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.
- Subjects
0301 basic medicine ,Male ,Clinical Biochemistry ,Disease ,Cohort Studies ,0302 clinical medicine ,Drug Discovery ,Receptors ,80 and over ,Medicine ,Aged, 80 and over ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,Interleukin-17 ,psoriasis ,Middle Aged ,dermatology ,sars-CoV-2 ,Italy ,biological therapy ,030220 oncology & carcinogenesis ,Cohort ,Biological Product ,COVID-19 ,Female ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Adult ,Aged ,Biological Products ,Biological Therapy ,Chronic Disease ,Humans ,Pandemics ,Psoriasis ,Receptors, Interleukin ,Risk Assessment ,Tumor Necrosis Factor-alpha ,Young Adult ,Cohort study ,Human ,medicine.medical_specialty ,Population ,03 medical and health sciences ,Settore MED/35 ,Internal medicine ,education ,Pharmacology ,Psoriasi ,Pandemic ,business.industry ,Biological product ,Interleukin ,medicine.disease ,Clinical trial ,030104 developmental biology ,SARS-CoV-2 ,Cohort Studie ,business - Abstract
Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
- Published
- 2021
18. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
- Author
-
Giulio Gualdi, Andrea Conti, Riccardo Balestri, Maria Rita Bongiorno, Annalisa Patrizi, Giuseppe Micali, Paolo Dapavo, Elia Rosi, M.T. Fierro, Luca Bianchi, S. Di Nuzzo, Matteo Megna, Angelo Cattaneo, R. Vezzoni, Francesca Prignano, C. Hansel, Sandra Giustini, Antonio Giovanni Richetta, A. Gambardella, Claudio Guarneri, S.P. Cannavò, Martina Burlando, Luca Stingeni, Giovanna Tilotta, K. Peris, S. Dastoli, Giulia Rech, Giuseppe Argenziano, Claudio Feliciani, Marina Venturini, Angelo V. Marzano, Paolo Gisondi, Giampiero Girolomoni, Mariateresa Rossi, D.M. Gambini, Maurizio Lombardo, Rossana Tiberio, Concetta Potenza, Lidia Sacchelli, Elisabetta Botti, Andrea Carugno, Marco Galluzzo, Paolo Pigatto, Maria Letizia Musumeci, F. Bardazzi, Pietro Quaglino, Pietro Rubegni, Iris Zalaudek, Nicoletta Bernardini, Andrea Chiricozzi, Mark S. Talamonti, Caterina Foti, Giovanni Pellacani, C. De Simone, Emanuele Trovato, Paolo Amerio, Giacomo Caldarola, A. Belloni Fortina, Federico Diotallevi, M C Fargnoli, Francesco Loconsole, Paola Savoia, Arianna Zangrilli, Stefano Piaserico, Andrea Parodi, A. M. Offidani, Steven Paul Nisticò, Gabriella Fabbrocini, Franco Rongioletti, Rosaria Fidanza, Cristina Mugheddu, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, G., Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, C., Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Marzano, A V, Bongiorno, Mr, Fargnoli, Mc, Nisticò, Sp, Cannavò, Sp, Fierro, Mt, Gambini, Dm, Musumeci, Ml, Richetta, Ag, Rossi, Mt, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M.T., Fidanza R., Foti C., Gambini D.M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel C., Megna M., Mugheddu C., Musumeci M.L., Patrizi A., Pellacani G., Piaserico S., Richetta A.G., Rosi E., Rossi M.T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.
- Subjects
medicine.medical_specialty ,Tildrakizumab ,Biolgical therapy ,COVID-19 ,Psoriasis ,Settore MED/35 ,Chronic Disease ,Emergencies ,Humans ,Italy ,Biological Therapy ,Ustekinumab ,medicine ,Adalimumab ,biologics ,Intensive care medicine ,Letter to the Editor ,psoriasi ,psoriasis ,covid-19 ,pandemic ,Emergencie ,Psoriasi ,Risankizumab ,business.industry ,SARS-CoV-2 ,medicine.disease ,dermatology ,Ixekizumab ,Guselkumab ,Infectious Diseases ,Secukinumab ,business ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,biologic ,COVID-19, psoriasis, biological therapies ,medicine.drug ,Human - Abstract
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.
- Published
- 2020
19. Italian guidelines in diagnosis and treatment of alopecia areata
- Author
-
Marta Muscianese, Giuseppe Monfrecola, Alfredo De Rossi, Stefano Astorino, Valentina Garelli, Francesco Lacarrubba, Annunziata Dattola, Giuseppe Micali, Andrea D'Arino, Alessandro Federico, Simone Garcovich, Luca Stingeni, Oriana Simonetti, Federico Bardazzi, Norma Cameli, Francesca Magri, Stefano Piaserico, Marta Carlesimo, Elena Marinello, Victor Desmond Mandel, Antonella Di Cesare, Katharina Hansel, Stefano Caccavale, Roberto D'Ovidio, Emi Dika, Annamaria Offidani, Donato Di Nunno, Flavia Pigliacelli, Lucia Villa, Cosimo Misciali, Teodora R Stan, Graziana Amendolagine, Colombina Vincenzi, Viviana Lora, Niccolò Rivetti, Maria Beatrice de Felici del Giudice, Maria Caterina Fortuna, Marina Talamonti, Claudio Feliciani, Cristina Guerriero, Alessandro Borghi, Francesca Bruni, Elisabetta Fulgione, Gabriella Fabbrocini, Andrea Carugno, Maria Carmela Annunziata, Paola Monari, Francesco Tassone, Gemma Caro, Maria C Arisi, Piergiacomo Calzavara-Pinton, Matteo Megna, Annalisa Patrizi, Graziella Babino, Bianca Maria Piraccini, Stefano Calvieri, Anna Belloni Fortina, Manuela Papini, Gloria Orlando, Stefania Barruscotti, Michele Cardone, Aurora Alessandrini, Iria Neri, Rosa Coppola, Michelangelo La Placa, Marco Galluzzo, Michela Starace, A Rossi, M Muscianese, BM Piraccini, M Starace, M Carlesimo, VD Mandel, A Alessandrini, S Calvieri, G Caro, A D’arino, A Federico, F Magri, F Pigliacelli, G Amendolagine, MC Annunziata, MC Arisi, G Babino, F Bardazzi, S Barruscotti, A Belloni Fortina, A Borghi, F Bruni, S Caccavale, P Calzavara Pinton, N Cameli, A Carugno, R Coppola, A Dattola, MB De Felici Del Giudice, A Di Cesare, E Dika, R D’ovidio, G Fabbrocini, C Feliciani, E Fulgione, M Galluzzo, S Garcovich, V Garelli, C Guerriro, K Hansel, M La Placa, F Lacarrubba, V Lora, E Marinello, M Megna, G Micali, C Misciali, G Monfrecola, I Neri, A Offidani, G Orlando, M Papini, A Patrizi, S Piaserico, N Rivetti, O Simonetti, TR Stan, L Stingeni, M Talamonti, F Tassone, L Villa, C Vincenzi, MC Fortuna, Rossi, A, Muscianese, M, Piraccini, B, Starace, M, Carlesimo, M, Mandel, V, Alessandrini, A, Calvieri, S, Caro, G, D'Arino, A, Federico, A, Magri, F, Pigliacelli, F, Amendolagine, G, Annunziata, M, Arisi, M, Astorino, S, Babino, G, Bardazzi, F, Barruscotti, S, Belloni Fortina, A, Borghi, A, Bruni, F, Caccavale, S, Calzavara-Pinton, P, Cameli, N, Cardone, M, Carugno, A, Coppola, R, Dattola, A, De Felici Del Giudice, M, Di Cesare, A, Dika, E, Dinunno, D, D'Ovidio, R, Fabbrocini, G, Feliciani, C, Fulgione, E, Galluzzo, M, Garcovich, S, Garelli, V, Guerriero, C, Hansel, K, La Placa, M, Lacarrubba, F, Lora, V, Marinello, E, Megna, M, Micali, G, Misciali, C, Monari, P, Monfrecola, G, Neri, I, Offidani, A, Orlando, G, Papini, M, Patrizi, A, Piaserico, S, Rivetti, N, Simonetti, O, Stan, T, Stingeni, L, Talamonti, M, Tassone, F, Villa, L, Vincenzi, C, Fortuna, M, Rossi, Alfredo, Muscianese, Marta, Piraccini, Bianca M, Starace, Michela, Carlesimo, Marta, Mandel, Victor D, Alessandrini, Aurora, Calvieri, Stefano, Caro, Gemma, D'Arino, Andrea, Federico, Alessandro, Magri, Francesca, Pigliacelli, Flavia, Amendolagine, Graziana, Annunziata, Maria C, Arisi, Maria Chiara, Babino, Graziella, Bardazzi, Federico, Barruscotti, Sefania, Belloni Fortina, Anna, Borghi, Alessandro, Bruni, Francesca, Caccavale, Stefano, Calzavara Pinton, Piergiacomo, Cameli, Norma, Carugno, Andrea, Coppola, Rosa, Dattola, Annunziata, De Felici Del Giudice, Maria B, Di Cesare, Antonella, Dika, Emi, D'Ovidio, Roberto, Fabbrocini, Gabriella, Feliciani, Claudio, Fulgione, Elisabetta, Galluzzo, Marco, Garcovich, Simone, Garelli, Valentina, Guerriro, Cristina, Hansel, Katharina, La Placa, Michelangelo, Lacarrubba, Francesco, Lora, Viviana, Marinello, Elena, Megna, Matteo, Micali, Giuseppe, Misciali, Cosimo, Monfrecola, Giuseppe, Neri, Iria, Offidani, Annamaria, Orlando, Gloria, Papini, Manuela, Patrizi, Annalisa, Piaserico, Stefano, Rivetti, Niccolo', Simonetti, Oriana, Stan, Teodora R, Stingeni, Luca, Talamonti, Maria, Tassone, Francesco, Villa, Lucia, Vincenzi, Colombina, Fortuna, Maria C, Rossi, A., Muscianese, M., Piraccini, B. M., Starace, M., Carlesimo, M., Mandel, V. D., Alessandrini, A., Calvieri, S., Caro, G., D'Arino, A., Federico, A., Magri, F., Pigliacelli, F., Amendolagine, G., Annunziata, M. C., Arisi, M. C., Astorino, S., Babino, G., Bardazzi, F., Barruscotti, S., Belloni Fortina, A., Borghi, A., Bruni, F., Caccavale, S., Calzavara-Pinton, P., Cameli, N., Cardone, M., Carugno, A., Coppola, R., Dattola, A., De Felici Del Giudice, M. B., Di Cesare, A., Dika, E., Dinunno, D., D'Ovidio, R., Fabbrocini, G., Feliciani, C., Fulgione, E., Galluzzo, M., Garcovich, S., Garelli, V., Guerriero, C., Hansel, K., La Placa, M., Lacarrubba, F., Lora, V., Marinello, E., Megna, M., Micali, G., Misciali, C., Monari, P., Monfrecola, G., Neri, I., Offidani, A., Orlando, G., Papini, M., Patrizi, A., Piaserico, S., Rivetti, N., Simonetti, O., Stan, T. R., Stingeni, L., Talamonti, M., Tassone, F., Villa, L., Vincenzi, C., and Fortuna, M. C.
- Subjects
medicine.medical_specialty ,corticosteroid ,Alopecia Areata ,MEDLINE ,Socio-culturale ,Alopecia areata, Autoimmunity, Guideline, Autoimmune Diseases, Evidence-Based Medicine, Hair Follicle, Italy ,Alopecia areata ,Autoimmunity ,Dermatology ,Disease ,Minoxidil ,Guideline ,Autoimmune Disease ,Autoimmune Diseases ,Food and drug administration ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Settore MED/35 ,Evidence-Based Medicine ,Hair Follicle ,Humans ,Italy ,alopecia areata ,autoimmunity ,guideline ,autoimmune diseases ,evidence-based medicine ,hair follicle ,humans ,italy ,Medicine ,topical immunotherapy ,integumentary system ,business.industry ,trichoscopy ,Evidence-based medicine ,medicine.disease ,Trichoscopy ,Clinical trial ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,business ,Human ,medicine.drug - Abstract
Alopecia Areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration (FDA). The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology (SIDeMaST) proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations.
- Published
- 2019
20. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)
- Author
-
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Rosa Giuseppa Angileri, Federico Bardazzi, Nicoletta Bernardini, Martina Burlando, Carlo G. Carrera, Andrea Chiricozzi, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Francesca Maria Gaiani, Marco Galluzzo, Claudia Giofré, Claudio Guarneri, Francesco Loconsole, Giovanna Malara, Lorenzo Marcelli, Matteo Megna, Stefano Piaserico, Marina Talamonti, Antonio Costanzo, Alessandra Narcisi, Gargiulo, L, Ibba, L, Malagoli, P, Angileri, R G, Bardazzi, F, Bernardini, N, Burlando, M, Carrera, C G, Chiricozzi, A, Dapavo, P, Dini, V, Fabbrocini, G, Gaiani, F M, Galluzzo, M, Giofré, C, Guarneri, C, Loconsole, F, Malara, G, Marcelli, L, Megna, M, Piaserico, S, Talamonti, M, Costanzo, A, and Narcisi, A
- Subjects
Infectious Diseases ,Dermatology - Abstract
Background: Guselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. Objectives: We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting. Methods: Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centers, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered. Results: At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤ 2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study. Conclusion: Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in "real-life" clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.
- Published
- 2023
21. Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab
- Author
-
F. Bruni, F. Bardazzi, M. Roda, C. Bellusci, Beatrice Raone, Corrado Zengarini, Costantino Schiavi, Zengarini C., Roda M., Schiavi C., Bruni F., Bardazzi F., Bellusci C., and Raone B.
- Subjects
genetic structures ,business.industry ,Elevated serum IgE ,Dermatology ,Omalizumab ,Atopic dermatitis ,medicine.disease ,eye diseases ,body regions ,medicine.anatomical_structure ,Chronic inflammatory skin condition ,Immunology ,Elevated IgE levels ,medicine ,vernal keratoconjunctivitis, atopic dermatitis, omalizumab ,sense organs ,Corneal scarring ,business ,Vernal keratoconjunctivitis ,Sensitization ,medicine.drug - Abstract
Atopic Dermatitis (AD) is a chronic inflammatory skin condition, defined as extrinsic when associated with elevated serum IgE levels and sensitization to various allergens1 . It is linked to multiple allergic disorders; among them, Vernal keratoconjunctivitis (VKC) is one of the worst affecting the eyes, which may lead to corneal scarring and vision loss if not treated properly.
- Published
- 2021
22. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
- Author
-
Luca Stingeni, Andrea Chiricozzi, Piergiorgio Malagoli, Anna Campanati, Marina Venturini, Antonio Costanzo, Anna Balato, Paolo Gisondi, Clara De Simone, Giampiero Girolomoni, Maria Letizia Musumeci, Aurora Parodi, Franco Rongioletti, Angelo Cattaneo, Claudia Lasagni, Santo Raffaele Mercuri, Valentina Dini, Francesca Prignano, Federico Bardazzi, Concetta Potenza, Claudio Guarneri, Ada Lo Schiavo, Ketty Peris, A. M. Offidani, Manuela Papini, Paolo Dapavo, Francesco Loconsole, Maria Laura Flori, Francesco Cusano, Maria Concetta Fargnoli, Stefano Piaserico, Marco Galluzzo, Paolo Amerio, Piergiacomo Calzavara Pinton, Luca Bianchi, Marina Talamonti, Luigi Naldi, Rossana Tiberio, G. Malara, Gisondi, Paolo, Talamonti, Marina, Chiricozzi, Andrea, Piaserico, Stefano, Amerio, Paolo, Balato, Anna, Bardazzi, Federico, Calzavara Pinton, Piergiacomo, Campanati, Anna, Cattaneo, Angelo, Dapavo, Paolo, De Simone, Clara, Dini, Valentina, Fargnoli, Maria C, Flori, Maria L, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Lo Schiavo, Ada, Malagoli, Piergiorgio, Malara, Giovanna, Mercuri, Santo R, Musumeci, Maria L, Naldi, Luigi, Papini, Manuela, Parodi, Aurora, Potenza, Concetta, Prignano, Francesca, Rongioletti, Franco, Stingeni, Luca, Tiberio, Rossana, Venturini, Marina, Bianchi, Luca, Costanzo, Antonio, Cusano, Francesco, Girolomoni, Giampiero, Offidani, Anna M, Peris, Ketty, Gisondi, P., Talamonti, M., Chiricozzi, A., Piaserico, S., Amerio, P., Balato, A., Bardazzi, F., Calzavara Pinton, P., Campanati, A., Cattaneo, A., Dapavo, P., De Simone, C., Dini, V., Fargnoli, M. C., Flori, M. L., Galluzzo, M., Guarneri, C., Lasagni, C., Loconsole, F., Lo Schiavo, A., Malagoli, P., Malara, G., Mercuri, S. R., Musumeci, M. L., Naldi, L., Papini, M., Parodi, A., Potenza, C., Prignano, F., Rongioletti, F., Stingeni, L., Tiberio, R., Venturini, M., Bianchi, L., Costanzo, A., Cusano, F., Girolomoni, G., Offidani, A. M., and Peris, K.
- Subjects
Quality of life ,Moderate to severe ,medicine.medical_specialty ,Consensus ,Delphi method ,Consensu ,Dermatology ,Plaque psoriasis ,Systemic inflammation ,Treat-to-target ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Settore MED/35 ,0302 clinical medicine ,Quality of life (healthcare) ,Psoriasis Area and Severity Index ,Psoriasis ,consensus ,plaque psoriasis ,quality of life ,systemic inflammation ,treatto-target ,medicine ,Intensive care medicine ,Original Research ,business.industry ,Treat to target ,Dermatology Life Quality Index ,medicine.disease ,Plaque psoriasi ,030220 oncology & carcinogenesis ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,business - Abstract
Introduction: Treat-to-target strategies are used in several chronic diseases to improve outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no consensus on targets, and guidance is needed to implement this strategy in clinical practice. The project ‘Treat to Target Italia’ was launched by a scientific board (SB) of 10 psoriasis experts to generate expert consensus recommendations. Methods: On the basis of the published literature, their clinical experience, and the results of a survey among Italian dermatologists, the SB identified four relevant topics: (1) clinical remission; (2) quality of life; (3) abrogation of systemic inflammation; (4) safety. They drafted 20 statements addressing these four topics and submitted them to a panel of 28 dermatologists, in a Delphi process, to achieve consensus (greater than 80% agreement). Results: Consensus was reached on all statements. Treatment goals defining clinical remission should include a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI90 response) or an absolute PASI score of less than or equal to 3. Patient’s quality of life and satisfaction are important targets. If PASI targets are achieved, there should be no or very low impact of psoriasis on quality of life [Dermatology Life Quality Index (DLQI) score less than or equal to 3]. If PASI or DLQI goals are not achieved within 3–4months, treatment should be changed. Abrogation of systemic inflammation may be crucial for preventing or delaying inflammatory comorbidities. Safety is an equally important target as efficacy. Conclusion: These 20 consensus statements define the parameters of a treat-to-target strategy for psoriasis in Italy. It is hoped that use of these in the management of patients with psoriasis will improve treatment outcomes and patient health-related quality of life.
- Published
- 2021
23. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)
- Author
-
Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Valentina Dini, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Alessandra Narcisi, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo, Malagoli, P., Dapavo, P., Pavia, G., Amoruso, F., Argenziano, G., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dini, V., Girolomoni, G., Guarneri, C., Loconsole, F., Narcisi, A., Sampogna, F., Travaglini, M., and Costanzo, A.
- Subjects
real-life experience ,Interleukin-17 ,Dermatology ,General Medicine ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,long-term efficacy ,Treatment Outcome ,ixekizumab ,Quality of Life ,Humans ,Psoriasis ,Dermatologic Agents ,Retrospective Studies - Abstract
Psoriasis is one of the commonest inflammatory skin diseases determining a very high impact on patients' quality of life and daily activities and relationships. Several biologic therapies have been approved through the years for the treatment of moderate-to-severe plaque psoriasis, and efficacy and safety profile have been analyzed in clinical trials. Ixekizumab is an immunoglobulin G subclass 4 monoclonal antibody that selectively targets and binds IL-17A with high specificity and affinity. Inhibiting IL-17A activity, ixekizumab reduces and turns down levels of inflammation, resulting in the clinical improvement of the disease. Long-term efficacy and safety profile of ixekizumab have been investigated and reported in the UNCOVER trials, but in literature there are only few studies based on real life experience. We present the efficacy and safety profile of ixekizumab in a cohort of 779 patients affected by moderate-to-severe plaque psoriasis and treated with ixekizumab in 11 Italian dermatology hospitals, with a follow-up of care until 192 weeks.
- Published
- 2022
24. Multiple itchy blisters and painful erosions on the hands
- Author
-
Marco Adriano Chessa, Camilla Loi, Federico Bardazzi, Michela Magnano, Carlotta Baraldi, Annalisa Patrizi, Federica Filippi, Chessa M.A., Filippi F., Baraldi C., Magnano M., Loi C., Patrizi A., and Bardazzi F.
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Blisters ,Dermatology ,medicine.symptom ,business - Published
- 2020
25. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
- Author
-
Paolo GISONDI, Maria C. FARGNOLI, Paolo AMERIO, Giuseppe ARGENZIANO, Federico BARDAZZI, Luca BIANCHI, Andrea CHIRICOZZI, Andrea CONTI, Monica CORAZZA, Antonio COSTANZO, Paolo DAPAVO, Clara DE SIMONE, Gabriella FABBROCINI, Claudio FELICIANI, Caterina FOTI, Giampiero GIROLOMONI, Claudio GUARNERI, Angelo V. MARZANO, Giuseppe MICALI, Annamaria OFFIDANI, Aurora PARODI, Giovanni PELLACANI, Stefano PIASERICO, Francesca PRIGNANO, Marco ROMANELLI, Franco RONGIOLETTI, Pietro RUBEGNI, Giuseppe STINCO, Luca STINGENI, Carlo F. TOMASINI, Marina VENTURINI, Ketty PERIS, Piergiacomo CALZAVARA-PINTON, Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, A., Conti, A., Corazza, M., Costanzo, A., Dapavo, P., DE Simone, C., Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, K., and Calzavara-Pinton, P.
- Subjects
Pandemic ,Female ,Humans ,Pandemics ,Pregnancy ,SARS-CoV-2 ,Ustekinumab ,COVID-19 ,Psoriasis ,Biological products ,Guideline ,Therapeutics ,Dermatology ,Infectious Diseases ,Settore MED/35 ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Human - Abstract
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
- Published
- 2022
26. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
- Author
-
Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo, Narcisi, A., Valenti, M., Gargiulo, L., Ibba, L., Amoruso, F., Argenziano, G., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dapavo, P., Dini, V., Franchi, C., Girolomoni, G., Guarneri, C., Loconsole, F., Sampogna, F., Travaglini, M., Malagoli, P., and Costanzo, A.
- Subjects
Infectious Diseases ,Dermatology ,psoriasis ,Biologics, psoriasis, psoriasis treatment ,Biologics ,psoriasis treatment - Abstract
Background: Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives: We conducted a 52-week retrospective study to assess the effectiveness and safety of tildrakizumab in a real-life setting. Methods: Our retrospective study included 237 consecutive adults with moderate-to-severe plaque psoriasis, enrolled in 10 different Italian centres, treated with tildrakizumab up to Week 52. Patient characteristics, comorbidities, previous treatments and the PASI (Psoriasis Area and Severity Index) score at each visit (baseline, Week 16, Week 28 and Week 52) were retrieved from the electronic medical records. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI with respect to baseline PASI were registered. Results: At Week 52, 90.91%, 73.55% and 58.68% of patients achieved a PASI reduction ≥75% (PASI 75), PASI 90 and PASI 100, respectively. An absolute PASI ≤ 2 was reached by 85.95% at Week 52. Compared with Phase 3 clinical trials, we observed similar rates of PASI 75/90 responses and higher percentages of patients achieving PASI 100. Patients who had not responded to previous biologic treatments and patients with cardio-metabolic comorbidities were significantly more likely to achieve PASI 100 at Week 28 and PASI 90 at Week 52. The higher body mass index did not interfere with the odds of reaching PASI 75/90/100 at each time point. No significant safety findings were recorded throughout the study, and none of the patients had to interrupt the treatment because of adverse events. Conclusion: Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in ‘real-life’ clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.
- Published
- 2022
27. Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients
- Author
-
Giorgia Comai, Gaetano La Manna, Lidia Sacchelli, Rossella Lacava, Federico Bardazzi, Annalisa Patrizi, Ambra Di Altobrando, Di Altobrando A., Lacava R., Patrizi A., Sacchelli L., La Manna G., Comai G., and Bardazzi F.
- Subjects
medicine.medical_specialty ,business.industry ,Psoriasis ,medicine ,MEDLINE ,Dermatology ,medicine.disease ,business ,Organ transplantation - Published
- 2020
28. The impact of psoriasis on quality of life of children and their caregivers: an Italian experience
- Author
-
Federica Filippi, Annalisi Patrizi, Faraz M. Ali, Marica Iommi, Vera Tengattini, Marco Adriano Chessa, Federico Bardazzi, Iria Neri, Paola Rucci, Bardazzi F., A Chessa M., Patrizi A., Iommi M., Rucci P., M Ali F., Filippi F., Tengattini V., and Neri I.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,business.industry ,Administration, Topical ,MEDLINE ,Dermatology ,psoriasis ,medicine.disease ,Health Surveys ,Severity of Illness Index ,Quality of life (healthcare) ,Caregivers ,Italy ,Child, Preschool ,Family medicine ,Psoriasis ,Quality of Life ,medicine ,Humans ,Female ,Dermatologic Agents ,Child ,business - Abstract
non disponibile
- Published
- 2021
29. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
- Author
-
Stefano Piaserico, Luca Bianchi, G. Malara, Marina Talamonti, C. Carrera, Federico Bardazzi, Concetta Potenza, Paolo Dapavo, Andrea Chiricozzi, Giuseppe Argenziano, Francesco Loconsole, Clara De Simone, Francesca Prignano, Andrea Conti, Piergiorgio Malagoli, Paolo Amerio, Franco Rongioletti, Nicola Balato, Aurora Parodi, K. Peris, Maria Concetta Fargnoli, Maria Letizia Musumeci, Ada Lo Schiavo, Antonio Costanzo, Chiricozzi, A., Costanzo, A., Fargnoli, M. C., Malagoli, P., Piaserico, S., Amerio, P., Argenziano, G., Balato, N., Bardazzi, F., Bianchi, L., Carrera, C. G., Conti, A., Dapavo, P., De Simone, C., Loconsole, F., Lo Schiavo, A., Malara, G., Musumeci, M. L., Parodi, A., Peris, K., Prignano, F., Rongioletti, F., Talamonti, M., and Potenza, C.
- Subjects
safety ,medicine.medical_specialty ,efficacy ,Dermatology ,Antibodies, Monoclonal, Humanized ,Interleukin-23 ,Severity of Illness Index ,Antibodies ,Psoriatic arthritis ,Settore MED/35 ,Psoriasis ,Ustekinumab ,Monoclonal ,medicine ,Adalimumab ,Humans ,Clinical Trials ,interleukin 23 ,Humanized ,plaque psoriasis ,Randomized Controlled Trials as Topic ,guselkumab ,plaque psoriasi ,Clinical Trials, Phase III as Topic ,Treatment Outcome ,business.industry ,medicine.disease ,Phase III as Topic ,Guselkumab ,Tolerability ,Body region ,Secukinumab ,business ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,medicine.drug - Abstract
Guselkumab, a subcutaneously administered fully human IgG1λ monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque psoriasis. The efficacy and safety of guselkumab were demonstrated in four randomized, double-blind, Phase III trials (VOYAGE 1 and 2, NAVIGATE, and ECLIPSE), which demonstrated high levels of clinical response over three years of continuous treatment, regardless of sex, age, body weight, and race, maintaining a favourable safety profile and long-term tolerability. Guselkumab was shown to be efficacious in patients with prior failure of other biologics, including adalimumab and ustekinumab, and was superior to both adalimumab and secukinumab in head-to-head trials. Guselkumab efficacy was also observed in the treatment of psoriasis localized in difficult-to-treat body regions including the scalp, palms and/or soles, and fingernails. Treatment with guselkumab improved health-related quality of life and patient-reported signs and symptoms. Guselkumab has a consistently favourable safety profile and is well tolerated over the long-term. Clinical development of guselkumab as a treatment is ongoing for other immune-mediated inflammatory diseases, including psoriatic arthritis, Crohn's disease, and ulcerative colitis. In the overall management of patients with plaque psoriasis, guselkumab is a robust treatment option with durable maintenance of response over time.
- Published
- 2021
30. Cutaneous complications of immunosuppression in 812 transplant recipients: a 40-year single center experience
- Author
-
Giulia Maria Ravaioli, Annalisa Patrizi, Federico Bardazzi, Salvatore Domenico Infusino, Camilla Loi, Bianca Maria Piraccini, and Infusino SD, Loi C, Ravaioli GM, Piraccini BM, Bardazzi F, Patrizi A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Population ,Dermatology ,Lower risk ,Single Center ,Skin Diseases ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,medicine ,Humans ,education ,Aged ,Retrospective Studies ,Immunosuppression Therapy ,education.field_of_study ,business.industry ,Actinic keratosis ,Immunosuppression ,Organ Transplantation ,Middle Aged ,medicine.disease ,Tacrolimus ,Female ,Skin cancer ,business ,Solid organ transplantation ,Immunosuppressive Agents ,oral transplant, nonmelanoma skin cancers,actinic keratoses, immunosuppressant drugs, tacrolimus, cyclosporine A - Abstract
Background: As a consequence of the improvement in survival after solid organ transplantation, to visit transplant recipients with neoplastic and non-neoplastic skin disorders due to immunosuppressive treatment has become common for dermatologists. Methods: Our endpoints were: 1) to investigate the most common skin diseases in a population of transplant recipients; 2) their associations with the type of immunosuppressant or transplant received; and 3) to compare our single center 40-year experience with the literature data. We retrospectively analyzed the clinical details of the adult patients transplanted in the years 1974-2014, visited for consultation at the Unit of Dermatology of our hospital. Results: Pathologic conditions were observed in more than 3/4 of 812 adults during the follow-up (mean 12.1 years): nonmelanoma skin cancers or actinic keratoses were seen in 44.0% (N.=357) of patients, non-neoplastic events in 55.2% (N.=448). Heart transplant had the statistically significant highest rate of NMSC and AK (52.6%, P=0.0352). Patients receiving cyclosporine A developed at least one non-melanoma skin cancer or actinic keratosis in 57.7% of cases (P=0.0001), while tacrolimus showed a lower risk (33%, P=0.0001). Conclusions: As transplant recipients are susceptible to skin changes, especially after immunosuppressant treatments, a dermatological follow-up should be scheduled for each patient.
- Published
- 2020
31. How infodemic during the COVID ‐19 outbreak influenced common clinical practice in an Outpatient Service of Severe Psoriasis
- Author
-
Simona Rosa, Paola Rucci, Rossella Lacava, Valeria Evangelista, Lidia Sacchelli, Annalisa Patrizi, Federico Bardazzi, Ambra Di Altobrando, Sacchelli L., Evangelista V., Di Altobrando A., Lacava R., Rucci P., Rosa S., Patrizi A., and Bardazzi F.
- Subjects
Adult ,Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,MEDLINE ,Dermatology ,Outpatient service ,Disease Outbreaks ,Psoriasis ,Ambulatory Care ,Humans ,Medicine ,Prospective Studies ,Severe psoriasis ,Intensive care medicine ,Aged ,Psoriasi ,Disease Outbreak ,SARS-CoV-2 ,business.industry ,COVID-19 ,Outbreak ,General Medicine ,Middle Aged ,medicine.disease ,Clinical Practice ,Prospective Studie ,Female ,business ,Human - Published
- 2020
- Full Text
- View/download PDF
32. Can COVID‐19 be a sexually transmitted disease? Posterity will judge
- Author
-
Gionathan Orioni, Filippo Viviani, Federico Bardazzi, Valeria Gaspari, Anna Lanzoni, Annalisa Patrizi, Gaspari V., Lanzoni A., Patrizi A., Orioni G., Viviani F., and Bardazzi F.
- Subjects
Sexually transmitted disease ,Male ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Dermatology ,Clinical Laboratory Technique ,COVID-19 Testing ,Pandemic ,Medicine ,Homosexuality, Male ,biology ,Betacoronaviru ,business.industry ,Coronavirus Infection ,SARS-CoV-2 ,Risk Factor ,COVID-19 ,Sexually Transmitted Diseases, Viral ,General Medicine ,biology.organism_classification ,Virology ,Fece ,business ,Coronavirus Infections ,Male Homosexuality ,Betacoronavirus ,Human - Published
- 2020
- Full Text
- View/download PDF
33. Multiple longstanding oral ulcers in an adolescent
- Author
-
Federico Bardazzi, Cosimo Misciali, Andrea Gabusi, Davide B Gissi, Camilla Loi, Federica Filippi, Gabusi A., Filippi F., Gissi D.B., Loi C., Misciali C., and Bardazzi F.
- Subjects
medicine.medical_specialty ,Adolescent ,business.industry ,No key words available ,MEDLINE ,Humans ,Medicine ,Dermatology ,Oral ulcers ,business ,Oral Ulcer - Abstract
No abstract available
- Published
- 2020
34. Missed induced bullous pemphigoid: When the anamnesis is the cure
- Author
-
Camilla Loi, Federico Bardazzi, Francesca Pepe, Annalisa Patrizi, Federica Filippi, Marco Adriano Chessa, Chessa M.A., Filippi F., Patrizi A., Loi C., Pepe F., and Bardazzi F.
- Subjects
Anamnesis ,Immunosuppression Therapy ,medicine.medical_specialty ,business.industry ,MEDLINE ,Dermatology ,medicine.disease ,Pharmaceutical Preparations ,Immunoglobulin G ,Pemphigoid, Bullous ,medicine ,Humans ,Bullous pemphigoid ,business ,Retrospective Studies - Published
- 2020
35. The COVID-19 outbreak in Italy: Preventive and protective measures adopted by the Dermatology Unit of Bologna University Hospital
- Author
-
Diego Abbenante, Federica Filippi, Federico Bardazzi, Annalisa Patrizi, Bianca Maria Piraccini, and Patrizi A, Bardazzi F, Filippi F, Abbenante D, Piraccini BM.
- Subjects
2019-20 coronavirus outbreak ,Letter ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,coronavirus ,Dermatology ,Unit (housing) ,Disease Outbreaks ,Hospitals, University ,COVID‐19 ,Pandemic ,Medicine ,Humans ,Letters ,COVID‐19 and dermatology ,Pandemics ,business.industry ,pandemic ,Outbreak ,COVID-19 ,General Medicine ,University hospital ,medicine.disease ,Italy ,preventive measures ,ARS-CoV-2, Hospital, dermatological unit ,Medical emergency ,business ,Coronavirus Infections - Abstract
At the time of writing, 22th April 2020, the pandemic in Italy has reached 187.327 total cases of contagion and 25.085 deaths3.The Dermatology Unit of S.Orsola-Malpighi University Hospital in Bologna,being situated within one of the areas most affected by the epidemic, has applied all possible measures to contrast the spread of the infection4-7.Our dermatological unit offers specialist consultations with an average of 50.000 admissions per year, resulting in a obvious high risk of contagion.
- Published
- 2020
36. Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
- Author
-
Ambra Di Altobrando, Federico Bardazzi, Patrizi Annalisa, Alessandro Pileri, Di Altobrando A., Patrizi A., and Bardazzi F.
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,viruses ,Pneumonia, Viral ,immunosuppressive therapy ,Dermatology ,Letter to Editor ,Autoimmune Disease ,SARS‐CoV‐2 ,Autoimmune Diseases ,Betacoronavirus ,Immunosuppressive Agent ,Blister ,COVID‐19 ,bullous disorders ,Pandemic ,Medicine ,Humans ,blistering disorders ,Letters to Editor ,Pandemics ,biology ,Betacoronaviru ,business.industry ,SARS-CoV-2 ,Coronavirus Infection ,COVID-19 ,biology.organism_classification ,Virology ,Bullous disorders ,Infectious Diseases ,business ,Coronavirus Infections ,Immunosuppressive Agents ,Human - Abstract
In this dramatic period where the whole world is affected by the outbreak of coronavirus disease 19 (COVID‐19), scientific data relating to the causative virus SARS‐CoV‐2 as well as the subsequent therapeutic repercussions on the management of other diseases should be divulged in order to share as much information as possible among experts in a timely manner.
- Published
- 2020
37. Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single-centre cross-sectional study
- Author
-
Federico Bardazzi, Bianca Maria Piraccini, Giulia Rech, Riccardo Balestri, E Rossi, Nazzarena Malavolta, Annalisa Patrizi, Michela Starace, Balestri, R, Rech, G, Rossi, E, Starace, M, Malavolta, N, Bardazzi, F, Patrizi, A, and Piraccini, B M
- Subjects
Adult ,Male ,medicine.medical_specialty ,Psoriasis, nail, arthotpaty, psoriatic arthritis ,Dermatology ,Nail Diseases ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Risk Factors ,Psoriasis ,Arthropathy ,medicine ,Humans ,Age of Onset ,Risk factor ,Subclinical infection ,030203 arthritis & rheumatology ,business.industry ,Arthritis, Psoriatic ,Enthesitis ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,medicine.anatomical_structure ,Disease Progression ,Nail (anatomy) ,Female ,medicine.symptom ,business ,Interphalangeal Joint - Abstract
The severity and clinical appearance of psoriatic arthritis(PsA) is markedly variable and the dermatologist plays an important role in identifying it at an early stage, before the joint damage becomes irreversible.1 Nail psoriasis(NP) is more frequent in patients with PsA than skin psoriasis2,3: about 50% of patients with NP complain of pain, stiffness or swelling of the interphalangeal joint in the absence of a diagnosis of arthropathy, suggesting that these symptoms may be a manifestation of a subclinical enthesitis potentially preceding PsA.4 This article is protected by copyright. All rights reserved.
- Published
- 2017
38. Successful treatment of refractory Hailey–Hailey disease with apremilast
- Author
-
Annalisa Patrizi, A. Di Altobrando, F. Bardazzi, Lidia Sacchelli, Di Altobrando A., Sacchelli L., Patrizi A., and Bardazzi F.
- Subjects
medicine.medical_specialty ,business.industry ,Inflammatory skin disease ,Dermatology ,medicine.disease ,Pemphigus ,Refractory ,Hailey–Hailey disease ,medicine ,Target therapy ,Apremilast ,business ,medicine.drug - Published
- 2020
39. Pachydermodactyly and thyroid disease: where is the link?
- Author
-
Carlotta Baraldi, Federico Bardazzi, Andrea Sechi, Miriam Leuzzi, Annalisa Patrizi, Camilla Loi, Leuzzi M., Loi C., Sechi A., Baraldi C., Patrizi A., and Bardazzi F.
- Subjects
medicine.medical_specialty ,business.industry ,Thyroid disease ,medicine ,Dermatology ,medicine.disease ,business ,Pachydermodactyly - Published
- 2019
40. Mucous Membrane Pemphigoid-Associated Malignancies: Case Series and a Brief Overview of the Literature
- Author
-
Andrea Sechi, Camilla Loi, Francesca Ferrara, Michelangelo La Placa, Riccardo Balestri, Annalisa Patrizi, Federico Bardazzi, Federico Tartari, and La Placa M, Balestri R, Tartari F, Sechi A, Ferrara F, Loi C, Patrizi A, Bardazzi F.
- Subjects
medicine.medical_specialty ,Population ,Dermatology ,paraneoplastic pemphigus ,Malignancy ,Gastroenterology ,blistering diseases ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,mucous membrane pemphigoid ,Internal medicine ,Genetics ,Medicine ,Cicatricial pemphigoid ,autoimmune bullous disorders ,education ,Molecular Biology ,education.field_of_study ,business.industry ,Autoantibody ,Cancer ,Articles ,medicine.disease ,Paraneoplastic pemphigus ,Oncology ,RL1-803 ,030220 oncology & carcinogenesis ,Adenocarcinoma ,business ,Mucous membrane pemphigoid, malignancy, autoimmune bullous disorders, paraneoplastic pemphigus, laminin-332, blistering diseases, laminin-5, anti-epiligrin, cicatricial pemphigoid, adenocarcinoma ,malignancy ,laminin-332 - Abstract
Background: Mucous membrane pemphigoid (MMP) is a heterogeneous group of blistering disorders affecting the mucosae with or without skin involvement, characterized by the presence of autoantibodies to components of the basement membrane zone, including the bullous pemphigoid antigen BP180 and β4 integrin. Current literature has shown that a minority of patients present circulating antibodies to laminin-332 and this population seems to be associated with a relatively high risk of malignancy. Objective: To present our personal case series of patients with MMP-associated malignancy from a dermatology university hospital. Methods: Twenty-two patients affected by MMP were seen in the period between 2001 and 2016; in 4 patients (18%) an associated cancer was detected. Results: These patients were 2 men and 2 women, with a mean age of 69.7 years (range, 48-83). The associated malignancies included a breast cancer, a pancreatic adenocarcinoma, a metastatic laryngeal carcinoma, and a hepatic carcinoma. All patients had negative results for both BP180 and laminin-332 autoantibodies. Conclusion: We confirm that MMP patients have a relatively high possibility of developing a solid cancer, but the autoantibody detection is not mandatory and is probably correlated with the severity of the disease.
- Published
- 2019
41. Idiopathic granulomatous vulvitis and subsequent oral granulomatosis: a diagnostic and therapeutic challenge
- Author
-
Federica Filippi, Lidia Sacchelli, Francesca Ferrara, Camilla Loi, F. Bardazzi, Vera Tengattini, Carlotta Baraldi, Annalisa Patrizi, Sacchelli L., Tengattini V., Baraldi C., Filippi F., Loi C., Ferrara F., Patrizi A., and Bardazzi F.
- Subjects
medicine.medical_specialty ,Dermatology ,Sarcoidosi ,Triamcinolone ,Vulvitis ,Diagnosis, Differential ,Crohn Disease ,Anti-Bacterial Agent ,Medicine ,Antifungal Agent ,Granuloma ,business.industry ,Crohn disease ,Lymecycline ,Middle Aged ,medicine.disease ,Drug Therapy, Combination ,Female ,Sarcoidosis ,medicine.symptom ,Differential diagnosis ,Econazole ,business ,Fusidic Acid ,Human - Abstract
Idiopathic granulomatous vulvitis and subsequent oral granulomatosis: a diagnostic and therapeutic challenge
- Published
- 2019
42. Merkel cell carcinoma: a prompt diagnosis to increase survival
- Author
-
Carlotta Baraldi, Federica Filippi, Alessandro Pileri, Valentina Ambrosini, Michela Magnano, Annalisa Patrizi, Stefano Fanti, Barbara Corti, Marta Malosso, Sabina Vaccari, Marco Adriano Chessa, Francesca Pepe, F. Bardazzi, Silvi Telo, Chessa M.A., Malosso M., Pepe F., Patrizi A., Telo S., Ambrosini V., Fanti S., Magnano M., Baraldi C., Corti B., Filippi F., Vaccari S., Pileri A., and Bardazzi F.
- Subjects
Aged, 80 and over ,Male ,Merkel cell carcinoma ,business.industry ,Dermatology ,Middle Aged ,medicine.disease ,Carcinoma, Merkel Cell ,Survival Rate ,Infectious Diseases ,Positron Emission Tomography Computed Tomography ,medicine ,Cancer research ,Humans ,Merkel cell carcinoma, survival, diagnosis ,Female ,business ,Aged - Abstract
not available
- Published
- 2019
43. Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis
- Author
-
F. Bardazzi, Lidia Sacchelli, Annalisa Patrizi, Camilla Loi, Sacchelli L., Patrizi A., Loi C., and Bardazzi F.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Combination therapy ,Dermatology ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Severity of illness ,medicine ,Humans ,Psoriasis ,Combined Modality Therapy ,In patient ,Plaque psoriasis ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Middle Aged ,Thalidomide ,Treatment Outcome ,Monoclonal ,Female ,Secukinumab ,Apremilast ,business ,medicine.drug - Published
- 2019
44. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience
- Author
-
F. Bardazzi, Francesca Peccerillo, Piergiorgio Malagoli, Luca Bianchi, A. Gambardella, S.P. Cannavò, Anna Balato, Paolo Gisondi, A. Offidani, Paolo Dapavo, Luca Stingeni, Andrea Chiricozzi, Francesca Prignano, Paolo Amerio, Andrea Conti, Martina Burlando, G. Malara, Stefano Piaserico, M C Fargnoli, Cristina Mugheddu, Giovanni Pellacani, C. De Simone, Conti, A, Peccerillo, F, Amerio, P, Balato, A, Bardazzi, F, Bianchi, L, Burlando, M, Cannavò, S P, Chiricozzi, A, Dapavo, P, De Simone, C, Fargnoli, M C, Gambardella, A, Gisondi, P, Malagoli, P, Malara, G, Mugheddu, C, Offidani, A M, Piaserico, S, Prignano, F, Stingeni, L, and Pellacani, G
- Subjects
Adult ,Male ,medicine.medical_specialty ,Injections, Subcutaneous ,Treatment outcome ,MEDLINE ,Dermatology ,Antibodies, Monoclonal, Humanized ,Drug Substitution ,Drug Administration Schedule ,Psoriasis ,medicine ,Humans ,Settore MED/35 - Malattie Cutanee e Veneree ,dermatologic agents ,business.industry ,Interleukin-17 ,Middle Aged ,medicine.disease ,Ixekizumab ,Treatment Outcome ,Multicenter study ,Monoclonal ,Female ,Secukinumab ,business - Published
- 2019
45. Sex and the PASI: patients affected by a mild form of psoriasis are more predisposed to have a more severe form of erectile dysfunction
- Author
-
Michela Magnano, Francesca Ferrara, Giulia Odorici, F. Bardazzi, Annalisa Patrizi, Riccardo Balestri, Bardazzi, F., Odorici, G, Ferrara, F., Magnano, M., Balestri, R., and Patrizi, A.
- Subjects
Male ,medicine.medical_specialty ,Dermatology ,Disease ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Erectile Dysfunction ,Surveys and Questionnaires ,Internal medicine ,Diabetes mellitus ,Psoriasis ,Severity of illness ,medicine ,Humans ,Mild form ,Endothelial dysfunction ,business.industry ,medicine.disease ,Infectious Diseases ,Erectile dysfunction ,Sexual dysfunction ,030220 oncology & carcinogenesis ,Physical therapy ,Female ,medicine.symptom ,business - Abstract
Background Psoriasis is a multi-systemic disease involving the skin and joints, but it is also characterized by endothelial dysfunction, which may cause sexual impotence and erectile dysfunction (ED), an embarrassing disease frequently neglected by dermatologists. Objective The principal objective was assessing the relationship between the severity of psoriasis and the severity of ED. We also investigated whether severity of psoriasis was related to International Index of Erectile Function-5 (IIEF-5) score, whether genital lesions worsened the IIEF-5 score, whether ED was related to factors such as diabetes, smoking and hypertension, and finally the overall the psychological factors felt by the patient. Methods We administered two questionnaires (one of which was the IIEF-5, a validated score to assess erectile dysfunction) to three groups of patients: 60 with mild psoriasis, 60 with severe psoriasis (assessed by Psoriasis Area Severity Index, PASI) and a control group including 60 patients without the disease. Results In the group of mild psoriasis, the patients who suffered from ED were the 56.67%, while in the group of severe psoriasis, ED affected the 46.68% of subjects. In the control group, ED was reported by the 23.33% of patients. The average IIEF-5 score was 18.81 for patients with mild psoriasis and 20.31 for patients with severe form. The difference in the average IIEF-5 scores between psoriatic (mild and severe cases) and control group was not statistically significant. Most patients with sexual dysfunction had also genital lesions; diabetes, smoking and hypertension were not related to lower IIEF-5 scores. The overall psychological profile of psoriatic patients was worse than that of the controls. Conclusion We concluded that ED was related to psoriasis, in particular to mild forms. Moreover, since ED is a marker of cardiovascular events, also related to negative impact on the quality of life, physicians should always investigate the presence of ED in clinical practice.
- Published
- 2016
46. Allergic contact dermatitis caused by glitter glue used as make-up containing methylchloroisothiazolinone
- Author
-
Federico Bardazzi, Michelangelo La Placa, Federica Guicciardi, Colombina Vincenzi, Giulia Maria Ravaioli, Martina Lambertini, Bianca Maria Piraccini, and Vincenzi C, Ravaioli GM, Lambertini M, Guicciardi F, Piraccini BM, Bardazzi F, La Placa M.
- Subjects
Adult ,medicine.medical_specialty ,case report, contact dermatitis, methylchloroisothiazolinone ,Dermatology ,Cosmetics ,Glitter ,chemistry.chemical_compound ,Anti-Infective Agents ,Adhesives ,medicine ,Immunology and Allergy ,Humans ,GLUE ,Allergic contact dermatitis ,business.industry ,Methylchloroisothiazolinone ,Patch Tests ,medicine.disease ,Thiazoles ,chemistry ,Dermatitis, Allergic Contact ,Female ,business ,Contact dermatitis ,Facial Dermatoses - Abstract
not available
- Published
- 2018
47. Reinventing the wheel: a simple topical treatment for psoriasis
- Author
-
Michela Magnano, Camilla Loi, Federico Bardazzi, Annalisa Patrizi, Francesca Ferrara, and Magnano M, Loi C, Ferrara F, Patrizi A, Bardazzi F.
- Subjects
Male ,medicine.medical_specialty ,business.industry ,Topical treatment ,Dermatology ,Middle Aged ,medicine.disease ,Administration, Cutaneous ,Medication Adherence ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Reinventing the wheel ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Psoriasis ,medicine ,Humans ,Medical physics ,Female ,Dermatologic Agents ,business ,Simple (philosophy) ,Retrospective Studies - Published
- 2018
48. Secukinumab in multi-failure psoriatic patients: the last hope?
- Author
-
Michela Magnano, Paola Sgubbi, Camilla Loi, A. M. Offidani, G. Odorici, Laura Tasin, Riccardo Balestri, Giulia Rech, F. Bardazzi, A. Campanati, Carlo Renè Girardelli, Andrea Conti, Annalisa Patrizi, Magnano, M, Loi, C, Patrizi, A, Sgubbi, P, Balestri, R, Rech, G, Tasin, L, Girardelli, C. R, Conti, A, Odorici, G, Campanati, A, Offidani, A. M, Bardazzi, F., DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, AREA MIN. 06 - Scienze mediche, and Da definire
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.drug_class ,Population ,Dermatology ,multi-failure ,psoriasis ,secukinumab ,Antibodies, Monoclonal, Humanized ,Chronic inflammatory disease ,Monoclonal antibody ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Psoriasis ,medicine ,Humans ,Treatment Failure ,education ,Aged ,psoriasi ,030203 arthritis & rheumatology ,Ankylosing spondylitis ,education.field_of_study ,business.industry ,Interleukin-17 ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Female ,Tumor necrosis factor alpha ,Secukinumab ,Dermatologic Agents ,business - Abstract
none 13 no Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent, and, in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also those agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, recently approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Magnano, M; Loi, C; Patrizi, A; Sgubbi, P; Balestri, R; Rech, G; Tasin, L; Girardelli, C. R; Conti, A; Odorici, G; Campanati, A; Offidani, A. M; Bardazzi, F. Magnano, M; Loi, C; Patrizi, A; Sgubbi, P; Balestri, R; Rech, G; Tasin, L; Girardelli, C. R; Conti, A; Odorici, G; Campanati, A; Offidani, A. M; Bardazzi, F.
- Published
- 2018
49. Analysis of immunological profile, clinical features and response to treatment in pemphigus
- Author
-
Federico Bardazzi, Riccardo Balestri, Alma Ismaili, Michelangelo La Placa, Alessia Barisani, Annalisa Patrizi, Bardazzi, F, Balestri, R, Ismaili, A, La Placa, M, Barisani, A, and Patrizi, A.
- Subjects
Adult ,Male ,0301 basic medicine ,Time Factors ,Enzyme-Linked Immunosorbent Assay ,Desmoglein ,Dermatology ,Pemphigu ,autoimmune bullous disorder ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Prospective Studies ,education ,Glucocorticoids ,Aged ,Autoantibodies ,Aged, 80 and over ,Autoimmune disease ,education.field_of_study ,030219 obstetrics & reproductive medicine ,Desmoglein 3 ,biology ,business.industry ,Desmoglein 1 ,Autoantibody ,Middle Aged ,autoantibodie ,medicine.disease ,Pemphigus ,Methotrexate ,Treatment Outcome ,030104 developmental biology ,Infectious Diseases ,Immunology ,biology.protein ,Female ,Dermatologic Agents ,Antibody ,business ,Follow-Up Studies ,medicine.drug - Abstract
BACKGROUND: Pemphigus is an autoimmune disease, characterized by the presence of serum autoantibodies against Desmoglein (Dsg) 1 and 3. It can affect the skin and/or the mucous membranes. Some authors found a correlation between the serum levels of autoantibodies, disease activity and clinical phenotype of pemphigus. Anti Dsg1 autoantibodies appear related to cutaneous phenotype, anti Dsg3 autoantibodies to mucosal involvement. METHODS: From 2011 to 2014, in patients with pemphigus, the serum levels of anti-Dsg1 and 3 antibodies were determined with enzyme-linked immuno-sorbent assay at diagnosis and after 6 months of different therapies. The correlations between levels of autoantibodies, clinical phenotype, clinical activity and response to therapy, were investigated. RESULTS: Thirty-five patients were included. Clinical phenotypes were: mucosal in 17 patients; mucous-cutaneous in 11; and cutaneous in 7. The status of anti-Dsg1 autoantibodies was significantly related to the cutaneous and mucous-cutaneous phenotypes both at diagnosis and after 6 months. The status of anti-Dsg3 autoantibodies was significantly related to the mucosal and mucous-cutaneous phenotypes only at first evaluation. No significant correlations were found between disease activity and the status of autoantibodies. No significant variations of autoantibody levels (between first and second sample) were found with regard to different therapies, except for the variation of anti-Dsg1 autoantibodies in one patient treated with systemic steroids and methotrexate. CONCLUSIONS: A correlation between serum levels of autoantibodies and clinical phenotype was found. Further studies over a longer follow-up period may better characterize the correlation between autoantibody levels, clinical activity and response to different therapies of pemphigus.
- Published
- 2017
50. Eruptive pruritic papular porokeratosis in a Caucasian woman: a transient inflammatory stage of porokeratosis
- Author
-
Cosimo Misciali, Federico Bardazzi, Annalucia Virdi, Annalisa Patrizi, Patrizi, A, Virdi, A, Misciali, C, and Bardazzi, F
- Subjects
Pathology ,medicine.medical_specialty ,Infectious Diseases ,business.industry ,Disseminated superficial porokeratosis ,Usually asymptomatic ,Medicine ,Dermatology ,Stage (cooking) ,business ,medicine.disease ,Porokeratosis - Abstract
Porokeratosis is usually asymptomatic, but a pruritic variant, called "eruptive pruritic papular porokeratosis" or "inflammatory disseminated superficial porokeratosis", has been described. We describe another case of pruritic porokeratosis in a 63--year--old Caucasian woman with a poor response to antihistamines and local treatments. EPPP is uncommon in non--Asiatic people, but probably it is underestimated. We consider it a transient inflammatory stage rather than a distinct entity of porokeratosis.
- Published
- 2017
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.